{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:34:26Z","timestamp":1782905666759,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cpcardiol.2022.101358","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T11:35:42Z","timestamp":1660908942000},"page":"101358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Impact of Tafamidis on Survival in a Real-World Community-Based Cohort"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-7887","authenticated-orcid":false,"given":"Kifah","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Macrinici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Wathen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil S.","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Minga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safwan","family":"Gaznabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hsiung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suha Haider","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Pursnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitasha","family":"Sarswat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101358_bib0001","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0002","first-page":"53","article-title":"Recent advances in the pharmacotherapy of TTR amyloidosis of the heart","volume":"5","author":"Shah","year":"2021","journal-title":"Vessel Plus"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0003","first-page":"e18221","article-title":"A systematic review of tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"13","author":"Singh","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0004","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0005","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0006","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0007","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0008","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1060028019888489","article-title":"Tafamidis: a first-in-class transthyretin stabilizer for transthyretin amyloid cardiomyopathy","volume":"54","author":"Park","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0009","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0010","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: a Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0011","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ejhf.2028","article-title":"Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis","volume":"23","author":"B\u00e9zard","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0013","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/jce.14541","article-title":"Effect of ICD implantation on cardiovascular outcomes in patients with cardiac amyloidosis: a systematic review and meta-anaylsis","volume":"31","author":"Halawa","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0014","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacep.2020.05.017","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: the growing need to look forward","volume":"6","author":"Kumar","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0015","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacc.2020.10.057","article-title":"Persistence of left atrial appendage thrombus in patients with cardiac amyloidosis","volume":"77","author":"El-Am","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0016","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-7800-2-17","article-title":"Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis","volume":"2","author":"Srkalovic","year":"2005","journal-title":"Int Semin Surg Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0017","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovi\u0107","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0018","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1002\/ehf2.13411","article-title":"Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey","volume":"8","author":"Tini","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0019","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101358_bib0021","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622002559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622002559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:58:01Z","timestamp":1758938281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622002559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0146280622002559"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101358","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Tafamidis on Survival in a Real-World Community-Based Cohort","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101358"}}